Funding will support clinical development of EPF-001, a first-in-class G9a inhibitor for sickle cell disease and beta thalassemia Company built on pioneering research from RIKEN and Tokyo University ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results